Overview

A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis

Status:
Completed

Trial end date:
2019-08-22

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of baricitinib in combination with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

Incyte Corporation